98 related articles for article (PubMed ID: 21683249)
1. Serpins and the complement system.
Beinrohr L; Murray-Rust TA; Dyksterhuis L; Závodszky P; Gál P; Pike RN; Wijeyewickrema LC
Methods Enzymol; 2011; 499():55-75. PubMed ID: 21683249
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding.
Rossi V; Bally I; Ancelet S; Xu Y; Frémeaux-Bacchi V; Vivès RR; Sadir R; Thielens N; Arlaud GJ
J Immunol; 2010 May; 184(9):4982-9. PubMed ID: 20351192
[TBL] [Abstract][Full Text] [Related]
3. Expression of active human C1 inhibitor serpin domain in Escherichia coli.
Lamark T; Ingebrigtsen M; Bjørnstad C; Melkko T; Mollnes TE; Nielsen EW
Protein Expr Purif; 2001 Jul; 22(2):349-58. PubMed ID: 11437612
[TBL] [Abstract][Full Text] [Related]
4. Regulation of C1-inhibitor function by binding to type IV collagen and heparin.
Patston PA; Schapira M
Biochem Biophys Res Commun; 1997 Jan; 230(3):597-601. PubMed ID: 9015369
[TBL] [Abstract][Full Text] [Related]
5. Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor.
Wijeyewickrema LC; Lameignere E; Hor L; Duncan RC; Shiba T; Travers RJ; Kapopara PR; Lei V; Smith SA; Kim H; Morrissey JH; Pike RN; Conway EM
Blood; 2016 Sep; 128(13):1766-76. PubMed ID: 27338096
[TBL] [Abstract][Full Text] [Related]
6. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement.
Weiss V; Engel J
Hoppe Seylers Z Physiol Chem; 1983 Mar; 364(3):295-301. PubMed ID: 6602754
[TBL] [Abstract][Full Text] [Related]
7. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
[TBL] [Abstract][Full Text] [Related]
8. Structure and function of C1 inhibitor.
Davis AE
Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
[TBL] [Abstract][Full Text] [Related]
9. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.
Bos IG; Lubbers YT; Roem D; Abrahams JP; Hack CE; Eldering E
J Biol Chem; 2003 Aug; 278(32):29463-70. PubMed ID: 12773530
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor.
Bos IG; de Bruin EC; Karuntu YA; Modderman PW; Eldering E; Hack CE
Biochim Biophys Acta; 2003 May; 1648(1-2):75-83. PubMed ID: 12758149
[TBL] [Abstract][Full Text] [Related]
11. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
Zahedi R; Wisnieski J; Davis AE
J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
[TBL] [Abstract][Full Text] [Related]
12. Identification of HIV-1 protease cleavage site in human C1-inhibitor.
Gerencer M; Burek V
Virus Res; 2004 Sep; 105(1):97-100. PubMed ID: 15325085
[TBL] [Abstract][Full Text] [Related]
13. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
Harpel PC; Cooper NR
J Clin Invest; 1975 Mar; 55(3):593-604. PubMed ID: 123251
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional aspects of C1-inhibitor.
Bos IG; Hack CE; Abrahams JP
Immunobiology; 2002 Sep; 205(4-5):518-33. PubMed ID: 12396012
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of the serpin domain of C1 inhibitor.
Coutinho M; Aulak KS; Davis AE
J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
[TBL] [Abstract][Full Text] [Related]
16. The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants.
Eldering E; Huijbregts CC; Nuijens JH; Hack CE
Behring Inst Mitt; 1993 Dec; (93):125-30. PubMed ID: 8172559
[No Abstract] [Full Text] [Related]
17. Characterization of recombinant C1 inhibitor P1 variants.
Eldering E; Huijbregts CC; Lubbers YT; Longstaff C; Hack CE
J Biol Chem; 1992 Apr; 267(10):7013-20. PubMed ID: 1551909
[TBL] [Abstract][Full Text] [Related]
18. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms.
Davis AE; Aulak K; Parad RB; Stecklein HP; Eldering E; Hack CE; Kramer J; Strunk RC; Bissler J; Rosen FS
Nat Genet; 1992 Aug; 1(5):354-8. PubMed ID: 1363816
[TBL] [Abstract][Full Text] [Related]
19. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.
Cai S; Davis AE
J Immunol; 2003 Nov; 171(9):4786-91. PubMed ID: 14568956
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1.
Murray-Rust TA; Kerr FK; Thomas AR; Wu T; Yongqing T; Ong PC; Quinsey NS; Whisstock JC; Wagenaar-Bos IC; Freeman C; Pike RN
Biochem J; 2009 Aug; 422(2):295-303. PubMed ID: 19522701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
